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Vaccine development for major global infec-
tious diseases will likely require strategies that 
induce strong T cell–mediated immunity, which 
is implicated in resistance to infections like 
HIV/AIDS, malaria, tuberculosis, and human 
papilloma and Epstein Barr viruses (1–5). One 
critical element of T cell–mediated immunity 
is the CD4+ helper T cell. These T cells are 
able to produce high levels of IFN-γ, exert cyto-
lytic activity on MHC class II–bearing targets, 
and help other elements of the immune response, 
such as antibody formation and CD8+ cytolytic 
killer cells including memory (6). HIV-infected 
patients who have a better clinical course and 
are long-term nonprogressors tend to have 
stronger CD4+ T cell responses to the virus (7, 8), 
and HIV-specifi c CD4+ T cells are able to pro-
mote the function of HIV- specifi c CD8+ T cells 
in vitro (9). It is therefore important to identify 
and harness principles of immune function that 
would improve CD4+ T cell immunity to HIV 
vaccines (10, 11).
Prior studies have used tissue culture sys-
tems, as well as adoptive transfer of DCs into 
animals and people, to show that these cells 
induce strong T cell–mediated immunity (for 
review see references 12–17). For example, 
isolated DCs are able to initiate CD4+ helper 
T cell responses in culture (18) and after reinfu-
sion into mice (19). When human (20) or mouse 
(21) DCs are loaded with antigen ex vivo and 
reinfused, the DCs expand antigen-specifi c 
helper cells that primarily produce IFN-γ and 
not IL-4; i.e., a Th1 type of CD4+ T cell that is 
thought to be valuable in host defense against 
viral infection (2, 3).
We have been developing a diff erent ap-
proach to study the function of DCs directly in 
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Current human immunodefi ciency virus (HIV) vaccine approaches emphasize prime boost 
strategies comprising multiple doses of DNA vaccine and recombinant viral vectors. We are 
developing a protein-based approach that directly harnesses principles for generating T cell 
immunity. Vaccine is delivered to maturing dendritic cells in lymphoid tissue by engineering 
protein antigen into an antibody to DEC-205, a receptor for antigen presentation. Here we 
characterize the CD4+ T cell immune response to HIV gag and compare effi cacy with other 
vaccine strategies in a single dose. DEC-205–targeted HIV gag p24 or p41 induces stronger 
CD4+ T cell immunity relative to high doses of gag protein, HIV gag plasmid DNA, or 
recombinant adenovirus-gag. High frequencies of interferon (IFN)-𝛄– and interleukin 2–
producing CD4+ T cells are elicited, including double cytokine-producing cells. In addition, 
the response is broad because the primed mice respond to an array of peptides in different 
major histocompatibility complex haplotypes. Long-lived T cell memory is observed. After 
subcutaneous vaccination, CD4+ and IFN-𝛄–dependent protection develops to a challenge 
with recombinant vaccinia-gag virus at a mucosal surface, the airway. We suggest that a 
DEC-targeted vaccine, in part because of an unusually strong and protective CD4+ T cell 
response, will improve vaccine effi cacy as a stand-alone approach or with other modalities.
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lymphoid tissues in situ and to harness the immunizing ca-
pacities of DCs in vaccine design. The approach is to deliver 
antigens within antibodies that selectively deliver vaccine 
proteins to DCs in lymphoid tissues. Our fi rst experiments 
have targeted DEC-205/CD205, an endocytic receptor (22, 
23) that was originally termed the NLDC-145 antigen and is 
expressed at high levels on DCs (24), particularly a subset of 
DCs, in lymphoid tissues (25). Although DEC-205 is ex-
pressed at high levels on several epithelia, and at low levels on 
many leukocytes (26, 27), the injected antibody primarily 
binds to DCs in the T cell areas (28). When antigens are in-
corporated into the anti–DEC-205 mAb, there is effi  cient 
antigen presentation on both MHC class I and II products; 
i.e., low doses of the targeted antigen relative to nontargeted 
antigen are required to present antigen in vivo (28–31). It is 
important to extend the concept of directed delivery of anti-
gen to DCs in situ to more clinically relevant antigens, to ad-
ditional immune readouts, and to comparisons with other 
vaccine modalities.
In our prior studies of antigen presentation by DCs in 
situ, we have chemically coupled the protein OVA to the 
anti-DEC antibody, or we have engineered the cDNA of the 
heavy chain of the antibody to express sequences for antigenic 
peptides in frame at its carboxy terminus. We regard the 
latter engineering method to be preferable in that fusion anti-
bodies can be expressed that reliably contain a single copy 
of the antigen on every heavy chain. For immunization to 
take place after injection of antigen within anti–DEC-205 
mAb, we also observed that it is necessary to overcome the 
normal capacity of the DEC-205+ DCs in situ to induce 
peripheral tolerance. This can be achieved by administering 
agonistic anti-CD40 mAb as a stimulus for the maturation of 
DCs in vivo (28–30). Using OVA as an antigen, we have 
shown that the combination of DC targeting and a matura-
tion stimulus improves CD4+ and CD8+ T cell responses 
in naive mice, as assessed with single MHC class I and II 
binding peptides (30).
Here we have engineered the p24 and p41 proteins from 
HIV gag into the heavy chain of anti–DEC-205 and studied 
the immune responses to the fusion mAb along with a matu-
ration stimulus. We fi nd that DC targeting with an anti-DEC-
205–HIV gag fusion mAb vaccine induces CD4+ T cell 
immunity of a quantity and quality that has not been seen be-
fore with safe vaccines. The CD4+ T cell response to a single 
dose of vaccine, as assessed by IFN-γ and IL-2 production, is 
much greater than that observed with plasmid gag DNA and 
Figure 1. Immunization of T cells with one dose of anti–DEC-p24 
fusion mAb vaccine. (A) BALB/c mice were injected i.p. with PBS, matu-
ration stimulus alone (25 μg αCD40 mAb and 50 μg poly IC), 5 μg con-
trol Ig-p24 or anti–DEC-p24 mAbs and maturation stimulus, and 5 μg 
anti–DEC-p24 without maturation stimulus. After 17 d, splenic CD8+ 
T cells (top) or CD4+ T cells (bottom) were restimulated with CD11c+ DCs 
and peptide (AMQMLKETI, p24 197–205, 2 μg/ml), HIV gag p24 peptide 
pools (2 μg/ml), or medium alone for 2 d. IFN-γ secretion was evaluated 
by ELISPOT. (B) As in A, but immunization of BALB/c mice with graded 
doses of anti–DEC-p24 and a maturation stimulus. Data are representa-
tive of two to four similar experiments with two mice pooled in 
each experiment.
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recombinant adenoviral gag vaccination, although these other 
approaches produce equal or more CD8+ IFN-γ–producing 
T cells. The immune response to anti–DEC-HIV gag com-
prises several potentially valuable features, including a broad 
response to many peptides in diff erent MHC backgrounds as 
well as CD4-dependent protection at mucosal surfaces.
RESULTS
DEC-205 targeting of HIV gag p24 enhances antigen 
presentation in vivo
To harness the antigen processing (32) and immunizing 
functions of DCs (16, 17) within intact lymphoid organs, we 
cloned HIV gag p24 protein in frame with the carboxyl ter-
minus of the heavy chain of an mAb to mouse DEC-205, an 
endocytic receptor for antigen presentation (22, 23). We also 
engineered the heavy chain of a control mAb that does not 
react with DCs. In prior studies, sequences for peptides were 
fused to the heavy chain (28, 31), but here we introduced 
gag protein (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20052005/DC1). The fusion mAbs 
were successfully expressed and contained heavy chains of 
75 kD as opposed to 50 kD for unmodifi ed mouse 
IgG1 (Fig. S1). Relative to the original anti–DEC-205 mAb, 
these fusion mAbs bound identically to DEC-205 transfec-
tants (not depicted).
To use fusion mAbs as vaccines, we needed to overcome 
the capacity of DEC-205–bearing DCs to induce tolerance 
(28, 29, 31). To do so, we injected a stimulus for DC matu-
ration together with the engineered mAb into 7–8-wk-old 
mice. We used a combination of the TLR3 ligand poly IC 
and an agonistic anti-CD40 mAb. In preliminary experiments, 
poly IC by itself did not lead to a primary immune response to 
anti–DEC-p24, but in keeping with prior observations (33), 
the combination of a TLR ligand and anti-CD40 did elicit 
stronger immunity. To detect T cell immunity, we used a 
library of 15-mer “mimetope” peptides staggered every 4 aa 
along the gag p24 sequence (34, 35). This library was divided 
into fi ve peptide pools (each containing 9–12 peptides), each 
of which was used to recall IFN-γ secretion in spleen cells 
from mice vaccinated with a single dose of anti–DEC-p24.
In initial experiments, an ELISPOT assay showed that 
BALB/c mice made T cell responses after vaccination with 
the combination of fusion mAb and maturation stimulus, but 
not with either alone (Fig. 1 A). The CD8+ T cell response 
was directed to peptides in p24 pool 2 (Fig. 1 A, top, white 
bar), which contained a previously defi ned gag 197–205 pep-
tide sequence presented on H-2Kd (Fig. 1 A, top, black bar; 
reference 36). In addition, CD4+ T cell responses were noted 
to peptides in p24 pools 1 and 3 (Fig. 1 A, bottom), and these 
involved IFN-γ production but no detectable IL-4 (not 
depicted). Interestingly, we had to administer higher doses of 
fusion mAb to elicit a CD8+ T cell response than a CD4+ T 
cell response. The former response to p24 pool 2 peptides 
was increasing when the dose of mAb was increased from 
5 to 20 μg/mouse (Fig. 1 B, top), whereas the helper re-
sponses to p24 pools 1 and 3 peptides could plateau between 
Figure 2. Strong CD4+ T cell responses to a single dose of anti–
DEC-p24 fusion mAb vaccine. (A) BALB/c mice were immunized s.c. 
with graded doses of anti–DEC-p24 or control Ig-p24 mAbs and matura-
tion stimulus. 19 d later, we assessed the percentage of IFN-γ+ CD4+ cells 
in gated CD3+ splenic T cells using gag p24 peptide pools. One of three 
similar experiments with two mice pooled in each experiment is shown. 
(B) As in A, but several experiments showing responses to 5 μg anti–DEC-
p24 or control Ig-p24 mAbs with maturation stimulus given either s.c. or 
i.p. to BALB/c mice. Background activity (<0.1%) of nonvaccinated mice 
boosted with the HIV gag p24 peptide pools was subtracted from the 
percentage of IFN-γ+ CD4+ cells. Each point represents two mice pooled 
in each experiment. (C) BALB/c or C57BL/6 mice were treated s.c. with PBS 
or 2 and 5 μg anti–DEC-p24 or control Ig-p24 mAbs, respectively, each 
with maturation stimulus. IFN-γ and IL-2 production was monitored at 
19 d. Numbers are the percentage of CD4+ cells producing cytokines to 
HIV gag p24 peptide pool 3 in BALB/c or pool 1 in C57BL/6 mice. These 
experiments were repeated two to four times with similar results. 
(D) Comparison of immune responses of wild-type and DEC-205−/− mice 
to 3 μg anti–DEC-p24 vaccine and maturation stimulus. IFN-γ secretion 
in response to HIV gag p24 peptide pools by CD4+ splenocytes as in A. 
Background frequencies (vaccinated mice boosted in medium only) were 
<0.01% in the top right quadrants. Data are representative of two 
similar experiments.
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1 and 5 μg/mouse (and some responses began to be detected 
with the control Ig-p24 vaccine; Fig. 1 B, bottom). We then 
turned to intracellular cytokine staining to monitor immuni-
zation because the response to a single dose of vaccine was 
large enough to be detected by this approach, and we con-
centrated our studies on the CD4+ T cell response because 
helper cells energize many components of immunity.
A strong IL-2– and IFN-𝛄–producing CD4+ T cell response 
to anti–DEC-p24
To establish the effi  ciency of DEC-205 targeting, we immu-
nized BALB/c mice with increasing doses of anti–DEC-p24 
mAb plus maturation stimuli or control Ig-p24. Targeting via 
DEC-205 was at least 100 times more eff ective at initiating 
IFN-γ–producing CD4+ T cell immunity (Fig. 2 A, com-
pare fi lled and open symbols) than control Ig-p24 or soluble 
gag protein (see below). When we assessed the route of injec-
tion, the i.p. route led to slightly higher immune responses 
than the s.c. route (Fig. 2 B, compare fi lled squares to circles), 
possibly because the delivery of the injected antibody solu-
tion was more reliable in the former case. When we moni-
tored both IFN-γ and IL-2 production in BALB/c and 
C57BL/6 mice, the majority of primed cells made both cy-
tokines (Fig. 2 C, top right quadrants), whereas lower fre-
quencies made only one of the cytokines. We also tested 
DEC-205−/− mice to show that DEC-205 was essential for 
immunization (Fig. 2 D). Thus, the use of anti–DEC-205 
mAb targeting greatly increases the effi  ciency with which 
protein antigens elicit T cell immunity, and when given as a 
single dose together with stimuli for DC maturation, the fre-
quency of primed CD4+ T cells is high.
Anti–DEC-p24 immunization enhances CD4+ T cell 
immunity relative to other immunization approaches
We compared the response to DC-targeted HIV gag p24 
with other modes of immunization. When we injected 1–50 
μg of soluble HIV p41 protein with anti-CD40 and poly 
IC maturation, or the combination of HIV protein with un-
conjugated anti–DEC-205 mAb, the immune responses were 
weak compared with DC-targeted HIV gag p24 with the 
same maturation stimulus (Fig. 3 A). A single dose of HIV 
protein likewise did not induce immunity by these assays 
when we tested other standard adjuvants, complete Freund’s 
adjuvant and alum (not depicted). We then tested plasmid 
DNA vaccines, which are currently in trials for immuniza-
tion of healthy volunteers (37–39). The CD4+ T cell re-
sponse to one or two injections of 50 μg of a gag p24 DNA 
vaccine was either weak or undetectable for each of the p24 
peptide pools (e.g., p24 pool 3 in Fig. 3 B). The response was 
likewise weak if the mice were injected with anti-CD40 and 
poly IC along with the DNA vaccine (not depicted). In con-
trast, the DNA vaccine did elicit a CD8+ T cell response to a 
dominant gag peptide for BALB/c mice in p24 peptide pool 2, 
comparable to that observed with the DC-targeted p24 pro-
tein vaccine (Fig. 3 C, top right quadrants). However, we 
Figure 3. Enhanced effi cacy of anti–DEC-p24 plus anti-CD40/poly 
IC relative to DNA and nontargeted protein vaccines. (A) C57BL/6 
mice were injected s.c. with maturation stimulus and the proteins indi-
cated above each panel. IFN-γ secretion was evaluated after 18 d in the 
spleen by intracellular cytokine staining as the percentage of IFN-γ CD4+ 
cells among CD3+ lymphocytes in response to HIV gag p24 peptide pool 4. 
Data are one of two to four similar experiments. (B) BALB/c mice were 
injected with 2 μg anti–DEC-p24 s.c. plus maturation stimulus, one or 
two doses of 50 μg DNA encoding HIV gag p24 protein i.m., or PBS. IFN-γ 
secretion in response to HIV gag p24 peptide pool 3 was evaluated as in A. 
Data shown are one of two to four similar experiments. (C) BALB/c mice 
were immunized i.p. with 5 μg anti–DEC-p24 or control Ig-p24 antibodies 
plus maturation stimulus, two doses of 50 μg DNA encoding HIV gag p24 
protein i.m., or PBS. IFN-γ secretion was evaluated as in A, but the re-
sponse to HIV gag p24 peptide pool 2 (containing a dominant peptide 
presented on MHC class I) and p24 pool 3 (containing a peptide pre-
sented on MHC class II) are shown for T cells directly stained for CD8 
expression. Data shown are from one of two similar experiments.
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could not detect IFN-γ–producing CD4+ T cell responses 
to two doses of DNA vaccine by intracellular cytokine stain-
ing relative to DC-targeted HIV gag p24 (Fig. 3 C, compare 
IFN-γ production by CD8− cells in the top left quadrants in 
the DNA- and anti–DEC-p24–vaccinated mice). Lastly, we 
tested a recombinant adenovirus-gag vaccine. A single dose 
i.m. induced clear-cut CD8+ T cell responses, clearly greater 
than anti–DEC-p24, but the CD4+ T cell responses remained 
low relative to anti–DEC-p24 (Table I and Fig. S2, available 
at http://www.jem.org/cgi/content/full/jem.20052005/DC1). 
We conclude that the targeting of a vaccine protein to DCs 
improves CD4+ T cell immunization relative to other ap-
proaches including DNA and recombinant adenovirus-gag 
vaccines, which are currently undergoing testing in humans.
DC-targeted HIV gag protein induces broad CD4+ 
T cell immunity
To ensure that the DEC-205 targeting strategy could induce 
immunity in diff erent MHC haplotypes, we studied three 
strains: BALB/c (H-2d), C57BL/6 (H-2b), and C3H (H-2k). 
In each, 0.2–2% of the CD4+ T cells became responsive to 
gag for at least two diff erent p24 peptide pools (Fig. 4 A). 
We are unable to fi nd reports in the literature of CD4+ T cell 
responses of this magnitude or breadth with other candidate 
 vaccines. When the reactive p24 pools were broken down into 
individual peptides, at least two diff erent mimetope peptides 
were reliably recognized in each of the strains (Table II). We 
also engineered the larger gag p41 protein into the anti–DEC-
205 heavy chain and showed that this protein in C57BL/6 
mice broadened the immune response further to include a 
third highly immunogenic peptide from the p17 portion of 
gag (Fig. 4 B). When we used graded doses of these individual 
peptides in the assay for T cell immunity, the mimetope pep-
tides gave optimal responses with 0.1 μg/ml, which indicate 
a good functional affi  nity of the T cells (Fig. 4 C, three sepa-
rate experiments). Therefore, a single dose of HIV protein tar-
geted to DCs results in a broad spectrum of peptides being 
effi  ciently recognized by CD4+ T cells, features that should 
reduce the chances of immune evasion by the virus.
Anti–DEC-p24 induces long-term memory CD4+ T cells
To test if long-term memory could be detected 19–30 wk after 
priming, we measured CD4+ T cell proliferation by CFSE 
 dilution in response to antigen. Eff ector–memory cells were no 
longer detected; i.e., T cells making IFN-γ within 6 h of anti-
gen rechallenge. However, memory T cells responding by 
proliferation to HIV gag were found in both BALB/c and 
C57BL/6 mice immunized with a single dose of anti–DEC-
p24 (Fig. 5, arrows), relative to the background responses seen 
with no peptide and a nonreactive peptide pool from gag p17 
(this background proliferation, termed the syngeneic mixed 
leukocyte reaction, is observed when DCs are cocultured 
with T cells in the absence of added antigens; reference 40). No 
memory cells were observed after vaccination with control 
Ig-p24 or with two injections of 50 μg of a gag p24 DNA 
(Fig. 5, fi rst and third rows). Therefore, long-term memory is 
detected 4–7.5 mo after a single-dose DC-targeted HIV vaccine.
Anti–DEC-p24 elicits protective immunity 
at a mucosal surface
To determine if immunity to gag p24 leads to protection, 
 especially at a mucosal surface distal to the skin vaccination site, 
Table I. CD4+ and CD8+ T cell responses to HIV gag p24 in BALB/c mice after a single immunization via anti−DEC-205 antibody 
or recombinant adenovirus
Experiment Spleen IFN-𝛄+ cells/104 CD4+ T cells
(no peptide/pool 3 restimulation)
IFN-𝛄+ cells/104 CD8+ T cells
 (no peptide/pool 2 restimulation)
No
vaccine
Control
Ig p24
anti-DEC
p24
adeno
5 × 105
adeno
2 × 107
No
vaccine
Control
Ig p24
anti-DEC
p24
adeno
5 × 105
adeno
2 × 107
1 A 8/5 2/4 2/101 4/14 ND 1/14 4/9 4/13 7/40 ND
B 4/5 3.4 7/50 6/7 ND 8/8 6/11 11/14 14/74 ND
2 A 9/15 13/19 16/125 14/26 16/24 16/14 16/14 15/17 15/59 13/326
B 2/3 2/5 4/72 3/7 3/12 3/4 2/4  5/17 2/160 2/432
BALB/c mice were immunized with a single dose of anti–DEC-205 or control Ig-gag p24 fusion antibody i.p. or the indicated dose of recombinant adenovirus gag vaccine i.m. 
The mAb fusion vaccine was given together with poly IC and anti-CD40 mAb. 18 d later, the frequency of IFN-γ–producing CD4+ and CD8+ T cells was measured by 
intracellular cytokine staining assay using the dominant peptide pools for these responses, pool 3 and pool 2, respectively. The underlined data contrasts the development of 
strong CD4+ T cell immunity to anti–DEC-205 gag fusion mAb and CD8+ T cell immunity to recombinant adenovirus.
Table II. HIV gag p24 mimetope peptides identifi ed from 15-mer 
peptide pools to stimulate IFN-γ secretion by CD4+ T cells 
in three MHC haplotypes after anti–DEC-p24 immunization
Strain HIV gag p24
Peptide pool
Reactive peptide
C3H 2 A A E W D R L H P V H A G P I (aa 209–223)
4 Y S P T S I L D I R Q G P K E (aa 277–291)
BALB/c 1 S P E V I P M F S A L S E G A (aa 165–179)
3 P V G E I Y K R W I I L G L N (aa 257–271)
C57BL/6 1 Q A I S P R T L N A W V K V V (aa 145–159)
4 V D R F Y K T L R A E Q A S Q (aa 297–311)
5 μg anti–DEC-p24 antibody in combination with 25 μg anti-CD40 and 50 μg poly 
IC was administered either i.p. to BALB/c mice or s.c. to C57BL/6 or C3H mice as in 
Fig. 4 A. After 17 d, splenic CD4+ T cells were restimulated with CD11c+ DCs and 
single peptides from the different reactive HIV gag p24 peptide pools (2 μg/ml) for 
2 d. IFN-γ secretion was evaluated by ELISPOT.
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we challenged the mice with recombinant vaccinia-gag intra-
nasally, fi rst at 2 wk after vaccination. The mice lost weight and 
developed high titers of virus in the lung over 7 d (>108 PFU/ml 
of tissue). By both criteria, reduced weight loss (Fig. 6, 
A, C, and E) and reduction in viral titers (Fig. 6, B, D, and F), 
both BALB/c and C57BL/6 mice were protected by the 
combination of anti–DEC-p24 plus a maturation stimulus, 
but were not protected when immunized with anti–DEC-
p24 alone, maturation stimulus alone, or control Ig-p24 plus 
a maturation stimulus (Fig. 6, A and B). Vaccinated mice 
were protected against recombinant vaccinia-gag but not vac-
cinia-OVA, indicating that protection was gag specifi c (not 
 depicted). We repeated the challenges but at longer time 
points, 12 and 24 wk after one dose of vaccine. Again, the DC-
 targeted vaccine protected the mice from a serious infection 
at a mucosal surface (not depicted). To evaluate the need for 
IFN-γ in protection, we studied IFN-γR knock out mice. 
The latter were not protected (Fig. 6, C and D), although the 
knockout mice did generate CD4+ T cell immunity comparably 
to wild-type mice (not depicted). Likewise, when we depleted 
CD4+ T cells from vaccinated mice before the challenge 
with vaccinia-gag, protection was ablated (Fig. 6, E and F) as 
 expected from prior work on CD4+ protection to vaccinia 
(41). Because we were observing resistance at a mucosal surface 
after s.c. injection of vaccine, we verifi ed prior information 
that anti–DEC-205 mAb is able to target systemically to DCs, 
including DCs in lymphoid tissues that drain mucosal surfaces 
(30). Specifi cally, we observed that p24 protein, when injected 
as a fusion anti–DEC-205 mAb, was primarily targeted to the 
CD8αhigh DC subset (which is also the DEChigh subset) in 
the spleen and mesenteric lymph node (Fig. S3, available at 
http://www.jem.org/cgi/content/full/jem.20052005/DC1). 
Figure 4. Breadth and strength of responses to DC-targeted HIV 
gag vaccine. (A) 5 μg anti–DEC-p24 mAb in combination with matura-
tion stimulus was administered either i.p. to BALB/c mice (top) or s.c. to 
C57BL/6 (middle) and C3H (bottom) mice. 18 d later, IFN-γ secretion in 
spleen CD3+ T cells was measured to medium or different HIV gag p24 
peptide pools. Data are representative of two to four experiments with 
two mice pooled in each experiment. (B) C57BL/6 mice were immunized 
s.c. with 5 μg anti–DEC-p41 or control Ig-p41 mAbs and maturation 
stimulus. IFN-γ secretion in spleen CD3+ T cells was measured at 15 d 
in response to medium or different HIV gag p24 and p17 peptide pools. 
Data shown are from one of three experiments. (C) In three experiments 
C57BL/6 mice were vaccinated s.c. with 2 μg anti–DEC-p24 with matura-
tion stimulus, and 19 d later, splenocytes were restimulated with graded 
doses of HIV gag p24 peptide number 6 from pool 1 (Q A I S P R T L N A W V K V V , 
p24 aa 145–159) or peptide number 8 from pool 4 (V D R F Y K T L R A E Q A S Q , 
p24 aa 297–311).
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Thus, IFN-γ–producing CD4+ T cells help to protect at 
a mucosal surface, and this resistance follows one dose of 
DC-targeted HIV gag fusion mAb vaccine.
DISCUSSION
Vaccine design has for some time depended on the discoveries 
of Pasteur that attenuated and inactivated microorganisms can 
induce specifi c and protective immunity (for review see refer-
ences 11 and 42). It has been diffi  cult to extend this strategy 
to many global infections because attenuated and inactivated 
vaccines are either diffi  cult to produce, potentially unsafe, 
or poorly immunogenic. As a result, alternative vaccines are 
being tested, such as naked plasmid DNA and recombinant 
modifi ed vaccinia-Ankara and adenoviruses (37–39). Eff orts 
Figure 5. Long-lived gag p24-memory to DC-targeted vaccine. 
BALB/c mice were immunized i.m. with two doses of 50 μg HIV gag p24 
DNA or i.p. with 5 μg anti–DEC-p24 and control Ig-p24 mAb with matu-
ration stimulus. C57BL/6 mice were similarly immunized, but the fusion 
antibodies and maturation stimulus were given s.c. CD4+ T cells were 
enriched by depleting MHC II+ and CD8+ cells from the lymph node 
(30 wk after BALB/c immunization) or spleen (at 19 wk for C57BL/6), CFSE 
labeled, and restimulated with CD11c+ DCs plus the peptide pools as indi-
cated, anti-CD3 and anti-CD28, or medium. Proliferation was evaluated 
by CFSE dilution at 4 d. Numbers are the percentage of CD4+ proliferating 
T cells. Control PBS-immunized mice showed similar proliferative re-
sponses to control Ig-p24 mAb or two doses of DNA gag p24 vaccine. 
Data are representative of two to three experiments on the same batch 
of immunized mice.
Figure 6. A single dose of anti–DEC-p24 vaccine elicits CD4-
dependent protection at a mucosal surface. (A and B) Groups of four to 
six BALB/c or C57BL/6 mice were immunized as in Fig. 1 and challenged at 
2–3 wk with 5 × 104 PFU of vaccinia-gag intranasally. Weight was mea-
sured for 6–7 d, and then lung virus titers were evaluated by plaque assay. 
Data are representative of two experiments in BALB/c and one in C57BL/6. 
(C and D) C57BL/6 or IFN-γR knockout mice were immunized s.c. with 
2 μg anti–DEC-p24 with maturation stimulus or with PBS and challenged 
with 2.5 × 104 PFU of vaccinia-gag 20 d later. (E and F) CD4+ T cells were 
depleted from C57BL/6 immunized mice with three doses of anti-CD4 mAb 
or control rat Ig 1–3 d before challenge. Data shown are one of three 
similar experiments. Weights are expressed as average body weight, 
whereas vaccinia plaque-forming titers (in CV-1 cells) are shown as a 
mean ± SD.
614 ANTI–DENDRITIC CELL HIV FUSION ANTIBODY VACCINE | Trumpfheller et al.
are underway to increase the immunogenicity of these safe 
vaccines. We have been taking a diff erent approach, which is 
to develop protein-based vaccines that directly rely on prin-
ciples of the immune system, to induce stronger T cell im-
munity and protection.
We are emphasizing DCs, which are pivotal cells for ini-
tiating adaptive immunity and memory, particularly T cell–
based responses. To better identify and harness the functions of 
DCs in intact lymphoid tissues, antigens are delivered within 
mAbs to specifi c DC receptors, beginning with a mAb to the 
endocytic receptor DEC-205 or CD205. The DEC-205 tar-
get represents a beginning because the biological outcome 
may be infl uenced by the specifi c DC receptor, the matura-
tion stimulus used to allow DCs to elicit immunity, and the 
subset of DCs expressing the receptor in question. Previ-
ously, we immunized mice with the model protein OVA 
that was chemically (but not stoichiometrically) conjugated 
to anti–DEC-205, and we studied the primary CD4+ T cell 
response to a single previously defi ned MHC class II–binding 
peptide in H-2b mice (30). Here we immunized mice of 
diff erent MHC haplotypes with a homogenous engineered 
mAb carrying the HIV gag protein, and we studied the 
breadth and quality of the CD4+ T cell response, including 
memory and CD4-dependent protection at a mucosal sur-
face. Our data reveal the potential of DCs in situ to elicit a 
CD4+ T cell response of a quality and quantity that has not 
been observed previously by other approaches to either study 
DC function or to develop safe vaccines.
The quality of the CD4+ T cell response was indicated 
fi rst by its breadth; i.e., the development of immunity in all 
three MHC haplotypes that were tested, including recogni-
tion of at least two gag peptides in each haplotype. This is 
in contrast to most analyses of protein vaccination in mice, 
which typically lead to immunization to a single peptide in 
one haplotype. We used mimetope peptides derived from an 
overlapping library of 15 mers spanning the full length of 
the gag p41 protein rather than naturally processed peptides. 
But even so, relatively low doses of the mimetope peptides 
(0.1 μg/ml) were required to activate the population of primed 
T cells in the immune assays. In addition, the observed re-
sponses were high even after a single dose of vaccine and in-
cluded the induction of memory and CD4+ T cell–based 
protection at a mucosal surface. We have emphasized a single 
dose of vaccine because single episodes of certain infections 
induce protective immunity, and it would be important to 
mimic this and identify principles that quickly lead to strong 
immunity with safe vaccines. The use of a single dose also 
provides a means to compare the effi  cacy of individual vac-
cines for their capacity to induce a primary immune response 
and ultimately memory. Additional research is required to 
study memory and secondary responses after targeted deliv-
ery of antigens to DCs in situ. Nonetheless, booster responses 
are evident, because in a companion paper in this issue 
(p. 599), the priming of helper CD4+ T cells with anti-DEC 
fusion mAbs sets the stage for a strong antibody response to 
a boost with free antigen or anti-DEC fusion mAb (43). In this 
latter study of antibody formation, we introduced a circum-
sporozoite protein from a malaria sporozoite into the anti–
DEC-205 mAb.
We noted that the DEC-targeted vaccine was superior in 
inducing CD4+ T cell responses relative to unconjugated 
protein with standard adjuvants, plasmid DNA, or recombi-
nant adenovirus. Interestingly, the gag DNA vaccines we 
prepared induced similar or better CD8+ T cell responses 
when compared with low doses of anti–DEC-205 gag vac-
cine, but the CD4+ T cell response to DNA vaccine was 
weak and lacked detectable memory (by a T cell proliferation 
assay). Likewise, the recombinant adenovirus that we tested 
induced strong CD8+ T cell responses but again much lower 
numbers of IFN-γ–producing CD4+ T cells relative to anti–
DEC-gag vaccine. DNA vaccines are capable of inducing 
some CD4+ T cell immunity in humans (44), but our data 
from mice suggest that the effi  ciency and breadth of CD4+ 
T cell immunization can be increased substantially using 
DC-targeted protein vaccines. It will be important to combine 
anti–DEC-205 delivery with other modalities like plasmid 
DNA and recombinant adenovirus because the improved 
CD4+ T cell help from DEC-205 targeting could greatly im-
prove the antibody and cytotoxic T cell immunity induced 
by these other vaccines.
Another interesting consequence of the DEC-targeted 
vaccine was that protective CD4+ T cell immunity was elic-
ited at a mucosal surface, the airway, which was distal to the 
skin vaccination site. This was observed in two mouse strains 
that were tested, C57BL/6 and BALB/c. Previously, we had 
noted that immunization of mice with anti–DEC-OVA al-
lowed for protection to a challenge with vaccinia-OVA, but 
we did not pursue long-term memory or the contribution of 
CD4+ T cells and IFN-γ to protection (30). Our results at 
fi rst glance seemed surprising because there is evidence that 
DCs capturing antigen from the skin immunize T cells with 
skin-homing properties, whereas DCs capturing antigen in a 
mucosal-associated lymphoid organ prime T cells that home 
to the mucosa (45). We suspect that our observations refl ect 
the capacity of mAb targeting to load DCs with antigen in 
lymph nodes that drain mucosal surfaces (Fig. S3; reference 30). 
It is also somewhat surprising to detect a role for CD4+ T cells 
in vaccinia protection because prior studies have demon-
strated a role for CD8+ T cells in defense of mice against 
vaccinia (46) or the pathogenic mouse pox, ectromelia virus 
(47). Nevertheless, Xu et al. (41) reported CD4+ T cell–
dependent protection via antibody formation to vaccinia. It is 
also possible that the strong CD4+ T cell responses induced 
by DEC-205 targeting provides direct resistance, e.g., through 
high level IFN-γ production and lysis of MHC class II–
bearing infected epithelial cells.
Given the normal tolerogenic function of at least some im-
mature DCs in vivo in the steady-state (28, 29, 48, 49), a DC 
maturation stimulus becomes an important component of a 
vaccine. Here we have used a combination of agonistic anti-
CD40 mAb and poly IC, the latter to ligate TLR3 receptors 
expressed by the DEC-205+ subset of DCs in mice (50). 
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 Interestingly, we did not observe a primary response to a single 
dose of DEC-205–targeted vaccine when poly IC was the 
only maturation stimulus, even though the DCs responded by 
remodeling cell surface markers in a way that is characteristic 
of DC maturation; i.e., increased expression of MHC class II 
and CD86 and decreased expression of CD119 IFN-γ recep-
tor (not depicted). It has been shown previously that these 
changes in surface phenotype are not by themselves suffi  cient 
to generate CD4+ and CD8+ T cell immunity by antigen-
presenting DCs (51). However, poly IC did enhance the adju-
vant eff ect of anti-CD40, as was also observed with tumor cell 
antigens when they were targeted to DCs in situ (52). Further 
research is needed to identify appropriate maturation stimuli 
for DC-targeted vaccines, including DCs in humans and non-
human primates, and these studies will need to include ana-
lyses of the induction of memory as well as more relevant 
protection assays than the vaccinia-gag model used here.
At this point, we have targeted a single receptor, DEC-
205/CD205, which is expressed by a subset of CD8+ DCs. 
Isolated and cultured CD8+ DCs produce IL-12 (17, 53), and 
when loaded with antigen and reinfused into mice, these DCs 
diff erentiate IFN-γ–producing T cells (21). Nonetheless, the 
control of antigen access to DCs and the maturation of the 
DCs in vivo represent intricate new areas of immunobiology. 
Other DC receptors, DC subsets, and immune responses—
particularly memory—will be important to investigate. 
DC-targeted vaccines off er potential advantages with respect 
to safety and ease of production, and we suggest they should 
be tested to improve effi  cacy as a stand-alone approach or in 
combination with other modalities.
MATERIALS AND METHODS
Animals. We used C57BL/6 (B6), C3H, and BALB/c mice from Taconic, 
IFN-γR knockouts (B6 background) from The Jackson Laboratory, and 
DEC-205−/− mice made by us. Mice were maintained under specifi c pathogen-
free conditions and used at 7–8 wk of age according to the guidelines of our 
Institutional Animal Care and Use Committee.
Fusion HIV gag mAbs and other vaccines. DNA for HIV-1 gag p24 or 
gag p41, i.e., aa 133–363 or aa 1–363 of gag p55 protein (from HIV isolate 
BH10), was cloned in frame into the COOH terminus of anti–DEC-205 
and control mAb heavy chains (28). Fusion mAbs were expressed by tran-
sient transfection (calcium-phosphate) in 293 cells in serum-free DMEM 
supplemented with Nutridoma SP (Roche), purifi ed on protein G columns 
(GE Healthcare), and characterized by SDS-PAGE and Western blotting 
(horseradish peroxidase sheep anti–mouse IgG [GE Healthcare] or α-p24 
[ImmunoDiagnostics]). Unconjugated anti–DEC-205 mAb expressed by 
stably transfected CHO cells was similarly purifi ed. Plasmid DNA gag p24 
vaccine was prepared by Aldevron. The plasmid was derived from consensus 
B gag (HIV Databases), codon optimized to improve expression, and cloned 
into the commercial plasmid pVAX1 (Invitrogen). The aa sequence encod-
ing the DNA gag p24 vaccine diff ered from the p24 protein sequence de-
rived from BH10 isolate at positions 138 (I→L) and 215 (V→L), respectively. 
Vaccine DNA was eluted into saline at 1 μg/μl, and endotoxin in purifi ed 
DNA was <5 EU/mg. To construct a recombinant adenoviral vector vac-
cine, the consensus B gag p24 plasmid was cloned into a commercial E1/E3-
deleted, replication-incompetent adenoviral type 5 vector (BD Biosciences). 
This vector was propagated in HEK 293 cells and purifi ed according to the 
manufacturer’s instructions (ViraKit for adenovirus 5; Virapur, LLC). Infec-
tious units were determined by cytopathic eff ects and subsequent measurement 
of HIV gag p24 by ELISA. One or two doses of 50 μg HIV-1 gag p24 DNA 
or one dose of recombinant adenovirus (5 × 105 or 2 × 107 PFU) was 
administered i.m.
Antigen targeting and maturation of DCs in vivo. Mice were injected 
i.p. or s.c. in the hind footpads with fusion mAb, unconjugated anti-DEC 
mAb, or HIV gag p41 protein (provided by R. Seder, National Institutes of 
Health [NIH], Bethesda, MD) without or with a stimulus for DC matura-
tion, which was 50 μg poly IC (InVivoGen) and 25 μg 1C10 agonistic 
anti-CD40 mAb (54) per mouse.
HIV gag peptides. Overlapping (staggered by 4 aa) gag p17 and p24 15-mer 
peptides were obtained from the NIH AIDS Reference Reagent Program 
(catalog no. 8117). Peptides, including the H-2Kd binding peptide p24 197–
205 (36), were also synthesized by the Proteomics Resource Center (The 
Rockefeller University). The 30- and 60-member gag p17 and p24 libraries 
were divided into 3 and 5 pools of 9 to 12 peptides, respectively. The respec-
tive gag p17 peptide pools span from aa 1–51 (pool 1), aa 41–91 (pool 2), and 
aa 81–135 (pool 3) of the HIV gag p17 protein, and the respective gag p24 
peptide pools span from aa 125–183 (pool 1), aa 173–231 (pool 2), aa 221–
279 (pool 3), aa 269–327 (pool 4), and aa 317–363 (pool 5) of the HIV gag 
p24 protein.
Assays for HIV gag-specifi c immune T cells. To identify HIV gag-
responsive T cells, spleen cells were stimulated with pools of peptides (2 μg/ml) 
or medium alone in the presence of 2 μg/ml of costimulatory anti-CD28 
(clone 37.51) for 6 h, adding 10 μg/ml brefeldin A (Sigma-Aldrich) for the 
last 4 h to accumulate intracellular cytokines. Cells were washed, incubated 
for 15 min at 4°C with 2.4G2 mAb to block Fcγ receptors, and stained with 
FITC- or PE-conjugated anti-CD3 (145-2C11) and PerCP-conjugated 
anti-CD4 (RM4-5) or anti-CD8 (S3-6.7) for 20 min at 4°C. The cells were 
permeabilized (Cytofi x/Cytoperm Plus; BD Biosciences) and stained with 
PE- or APC-anti–IFN-γ (XMG 1.2) and PE- or APC-anti–IL-2 (JESG-
5H4) mAbs for 15 min at room temperature (BD Biosciences). We used a 
FACSCalibur with data analysis in FlowJo (Tree Star). All plots were gated 
on low forward and side scatter CD3+ cells. For ELISPOT assays, we re-
stimulated for 2 d CD4+ or CD8+ T cells, purifi ed by positive selection, 
with CD11c+ spleen DCs and HIV gag p24 peptide pools (2 μg/ml), 
an H-2Kd–restricted peptide (2 μg/ml; AMQMLKETI, p24 197–205), or me -
dium alone. DCs were enriched from the spleens or mesenteric lymph nodes 
dissociated with collagenase (collagenase D; Roche) using anti-CD11c–
coated magnetic beads (Miltenyi Biotec). We used CFSE (107 cells/ml, 
1 μM, 10 min, 37°C; Invitrogen) dilution to assess proliferation of primed 
T cells in response to antigen. CD4+ T cells from the spleen or lymph node 
were obtained by depleting MHC class II+ and CD8+ cells. After labeling 
with CFSE, the T cells were added at 10–30 CD4+ T cells per spleen CD11c+ DC 
in the presence of HIV gag p24 peptide pools (2 μg/ml), nonreactive pep-
tide pool, medium alone, or anti-CD3 (0.1 μg/ml) and anti-CD28 (2 μg/ml; 
positive control) for 4 d in 1 ml round-bottom tubes.
Antibody-mediated delivery of HIV gag p24 to DCs in lymphoid 
tissues. CD11c+ DCs were enriched from lymphoid organs of mice given 
10 μg anti–DEC-p24 or control Ig-p24 1 d earlier s.c. The cells were preincu-
bated with 2.4G2 culture medium to block Fcγ receptors, washed, and incu-
bated with PE-conjugated CD11c (HL3; BD Biosciences) and APC-conjugated 
CD8 (53-6.7; BD Biosciences) for 20 min at 4°C. Permeabilized cells (Cytofi x/
Cytoperm Plus) were stained with FITC–anti-p24 mAb (KC57-FITC; 
Coulter) for 15 min at room temperature and evaluated by fl ow cytometry.
Protection experiments to an airway challenge with recombinant 
vaccinia-gag. 2.5–5 × 104 PFU recombinant vaccinia-gag virus or vaccinia-
OVA control were applied intranasally to anesthetized mice (30, 55). In some 
experiments, vaccinated B6 mice were depleted of CD4+ T cells by injection 
with 500 μg GK 1.5 mAb 1–3 d before challenge. To assess protection, we 
monitored body weights daily for 6–7 d, and then the animals were killed 
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 (because of considerable weight loss) and the lungs harvested to prepare ex-
tracts by physical disruption. Weight data are expressed as average body weight 
from groups of four to six mice, whereas vaccinia titers in a plaque-forming 
assay (in CV-1 cells) are shown as a mean ± SD for four to six mice.
Online supplemental material. Fig. S1 shows the constructs we prepared 
to express fusion mAbs that carry HIV gag, as well as SDS-PAGE electro-
phoresis and immunoblot analysis of the control Ig-p24 and anti–DEC-p24 
 fusion mAbs. Fig. S2 shows that recombinant adenovirus-gag induces a strong 
CD8+ T cell response, whereas anti–DEC-p24 elicits a robust CD4+ T cell 
response. Fig. S3 shows the systemic distribution of p24 (in spleen and mesen-
teric lymph node, CD8α+ and DEC-205+ DCs) after anti–DEC-205  targeting 
s.c. Figs. S1–S3 are available at http://www.jem.org/cgi/content/full/
jem.20052005/DC1.
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